annual EBIT:
-$504.55M+$37.91M(+6.99%)Summary
- As of today (July 7, 2025), RARE annual earnings before interest & taxes is -$504.55 million, with the most recent change of +$37.91 million (+6.99%) on December 31, 2024.
- During the last 3 years, RARE annual EBIT has fallen by -$80.99 million (-19.12%).
- RARE annual EBIT is now -7569.02% below its all-time high of -$6.58 million, reached on December 31, 2011.
Performance
RARE EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBIT:
-$135.43M-$17.55M(-14.88%)Summary
- As of today (July 7, 2025), RARE quarterly earnings before interest & taxes is -$135.43 million, with the most recent change of -$17.55 million (-14.88%) on March 31, 2025.
- Over the past year, RARE quarterly EBIT has increased by +$18.95 million (+12.28%).
- RARE quarterly EBIT is now -261.35% below its all-time high of $83.94 million, reached on December 31, 2018.
Performance
RARE quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBIT:
-$485.59M+$18.95M(+3.76%)Summary
- As of today (July 7, 2025), RARE TTM earnings before interest & taxes is -$485.59 million, with the most recent change of +$18.95 million (+3.76%) on March 31, 2025.
- Over the past year, RARE TTM EBIT has increased by +$63.41 million (+11.55%).
- RARE TTM EBIT is now -10500.11% below its all-time high of -$4.58 million, reached on December 31, 2012.
Performance
RARE TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
RARE EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +7.0% | +12.3% | +11.6% |
| 3 y3 years | -19.1% | +6.7% | -10.0% |
| 5 y5 years | -26.7% | -22.5% | -73.9% |
RARE EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -19.1% | +23.4% | -23.6% | +39.6% | -1.2% | +26.6% |
| 5 y | 5-year | -231.8% | +23.4% | -496.5% | +39.6% | -219.3% | +26.6% |
| alltime | all time | -7569.0% | +23.4% | -261.4% | +39.6% | <-9999.0% | +26.6% |
RARE EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | -$135.43M(+14.9%) | -$485.59M(-3.8%) |
| Dec 2024 | -$504.55M(-7.0%) | -$117.88M(+0.3%) | -$504.55M(+1.7%) |
| Sep 2024 | - | -$117.50M(+2.4%) | -$496.23M(-4.6%) |
| Jun 2024 | - | -$114.78M(-25.7%) | -$520.06M(-5.3%) |
| Mar 2024 | - | -$154.38M(+40.9%) | -$549.00M(+1.2%) |
| Dec 2023 | -$542.46M(-17.6%) | -$109.56M(-22.5%) | -$542.46M(-4.9%) |
| Sep 2023 | - | -$141.33M(-1.7%) | -$570.31M(-12.7%) |
| Jun 2023 | - | -$143.72M(-2.8%) | -$653.29M(-1.2%) |
| Mar 2023 | - | -$147.84M(+7.6%) | -$661.37M(+0.4%) |
| Dec 2022 | -$658.71M(+55.5%) | -$137.41M(-38.7%) | -$658.71M(+2.9%) |
| Sep 2022 | - | -$224.31M(+47.8%) | -$639.93M(+33.4%) |
| Jun 2022 | - | -$151.81M(+4.6%) | -$479.75M(+8.7%) |
| Mar 2022 | - | -$145.18M(+22.4%) | -$441.39M(+4.2%) |
| Dec 2021 | -$423.56M(+178.5%) | -$118.63M(+85.0%) | -$423.56M(+32.1%) |
| Sep 2021 | - | -$64.13M(-43.5%) | -$320.67M(+1.3%) |
| Jun 2021 | - | -$113.45M(-10.9%) | -$316.49M(+87.4%) |
| Mar 2021 | - | -$127.34M(+708.9%) | -$168.88M(+11.1%) |
| Dec 2020 | -$152.07M(-61.8%) | -$15.74M(-73.7%) | -$152.07M(-32.8%) |
| Sep 2020 | - | -$59.95M(-275.5%) | -$226.43M(-18.9%) |
| Jun 2020 | - | $34.16M(-130.9%) | -$279.19M(-32.3%) |
| Mar 2020 | - | -$110.53M(+22.7%) | -$412.30M(+3.5%) |
| Dec 2019 | -$398.31M(+102.1%) | -$90.11M(-20.0%) | -$398.31M(+77.6%) |
| Sep 2019 | - | -$112.70M(+13.9%) | -$224.26M(+11.5%) |
| Jun 2019 | - | -$98.96M(+2.5%) | -$201.21M(+2.1%) |
| Mar 2019 | - | -$96.54M(-215.0%) | -$197.15M(+0.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2018 | -$197.10M(-38.1%) | $83.94M(-193.6%) | -$197.10M(-46.3%) |
| Sep 2018 | - | -$89.65M(-5.5%) | -$367.26M(+1.6%) |
| Jun 2018 | - | -$94.90M(-1.6%) | -$361.33M(+4.8%) |
| Mar 2018 | - | -$96.49M(+11.9%) | -$344.87M(+8.3%) |
| Dec 2017 | -$318.34M(+28.4%) | -$86.23M(+3.0%) | -$318.34M(+5.2%) |
| Sep 2017 | - | -$83.71M(+6.7%) | -$302.66M(+6.3%) |
| Jun 2017 | - | -$78.44M(+12.1%) | -$284.73M(+7.7%) |
| Mar 2017 | - | -$69.95M(-0.8%) | -$264.34M(+6.6%) |
| Dec 2016 | -$248.01M(+67.9%) | -$70.55M(+7.2%) | -$248.01M(+6.2%) |
| Sep 2016 | - | -$65.78M(+13.3%) | -$233.62M(+12.4%) |
| Jun 2016 | - | -$58.05M(+8.3%) | -$207.77M(+15.5%) |
| Mar 2016 | - | -$53.62M(-4.5%) | -$179.86M(+21.7%) |
| Dec 2015 | -$147.74M(+160.2%) | -$56.16M(+40.6%) | -$147.74M(+36.1%) |
| Sep 2015 | - | -$39.94M(+32.5%) | -$108.52M(+28.5%) |
| Jun 2015 | - | -$30.14M(+40.2%) | -$84.42M(+24.3%) |
| Mar 2015 | - | -$21.50M(+26.9%) | -$67.94M(+19.7%) |
| Dec 2014 | -$56.78M(+75.9%) | -$16.94M(+7.0%) | -$56.78M(+15.0%) |
| Sep 2014 | - | -$15.84M(+15.9%) | -$49.36M(+19.6%) |
| Jun 2014 | - | -$13.66M(+32.1%) | -$41.29M(+15.1%) |
| Mar 2014 | - | -$10.34M(+8.5%) | -$35.87M(+11.1%) |
| Dec 2013 | -$32.28M(+101.9%) | -$9.53M(+22.7%) | -$32.28M(+18.1%) |
| Sep 2013 | - | -$7.76M(-5.9%) | -$27.34M(+39.6%) |
| Jun 2013 | - | -$8.25M(+22.2%) | -$19.57M(+72.8%) |
| Mar 2013 | - | -$6.75M(+47.3%) | -$11.33M(+147.3%) |
| Dec 2012 | -$15.98M(+143.0%) | -$4.58M | -$4.58M |
| Dec 2011 | -$6.58M | - | - |
FAQ
- What is Ultragenyx Pharmaceutical Inc. annual earnings before interest & taxes?
- What is the all time high annual EBIT for Ultragenyx Pharmaceutical Inc.?
- What is Ultragenyx Pharmaceutical Inc. annual EBIT year-on-year change?
- What is Ultragenyx Pharmaceutical Inc. quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Ultragenyx Pharmaceutical Inc.?
- What is Ultragenyx Pharmaceutical Inc. quarterly EBIT year-on-year change?
- What is Ultragenyx Pharmaceutical Inc. TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Ultragenyx Pharmaceutical Inc.?
- What is Ultragenyx Pharmaceutical Inc. TTM EBIT year-on-year change?
What is Ultragenyx Pharmaceutical Inc. annual earnings before interest & taxes?
The current annual EBIT of RARE is -$504.55M
What is the all time high annual EBIT for Ultragenyx Pharmaceutical Inc.?
Ultragenyx Pharmaceutical Inc. all-time high annual earnings before interest & taxes is -$6.58M
What is Ultragenyx Pharmaceutical Inc. annual EBIT year-on-year change?
Over the past year, RARE annual earnings before interest & taxes has changed by +$37.91M (+6.99%)
What is Ultragenyx Pharmaceutical Inc. quarterly earnings before interest & taxes?
The current quarterly EBIT of RARE is -$135.43M
What is the all time high quarterly EBIT for Ultragenyx Pharmaceutical Inc.?
Ultragenyx Pharmaceutical Inc. all-time high quarterly earnings before interest & taxes is $83.94M
What is Ultragenyx Pharmaceutical Inc. quarterly EBIT year-on-year change?
Over the past year, RARE quarterly earnings before interest & taxes has changed by +$18.95M (+12.28%)
What is Ultragenyx Pharmaceutical Inc. TTM earnings before interest & taxes?
The current TTM EBIT of RARE is -$485.59M
What is the all time high TTM EBIT for Ultragenyx Pharmaceutical Inc.?
Ultragenyx Pharmaceutical Inc. all-time high TTM earnings before interest & taxes is -$4.58M
What is Ultragenyx Pharmaceutical Inc. TTM EBIT year-on-year change?
Over the past year, RARE TTM earnings before interest & taxes has changed by +$63.41M (+11.55%)